Novel COVID-19 Vaccine May Provide Protection for Cancer Patients With B-cell Deficiencies
The peptide-based vaccine induces a T cell-dependent response NEW ORLEANS – CoVac-1, a new vaccine against SARS-CoV-2, induced T-cell...
The peptide-based vaccine induces a T cell-dependent response NEW ORLEANS – CoVac-1, a new vaccine against SARS-CoV-2, induced T-cell...
Findings may have implications for treating patients of African descent PHILADELPHIA – Certain genetic variants found in prostate tumors...
Researchers identified mutational signatures characteristic of chemotherapy exposure PHILADELPHIA – Researchers identified a higher rate of clonal hematopoiesis (CH)...
PHILADELPHIA – The American Association for Cancer Research (AACR) will present the 2023 AACR Distinguished Public Service Awards for...
PHILADELPHIA – The American Association for Cancer Research (AACR) will present the 2024 AACR Distinguished Public Service Award for...
SAN ANTONIO – Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the...
SAN DIEGO – Survivors of childhood cancer who consumed more total sugar, added sugar, and sugar-sweetened beverages had more...
Next-generation sequencing for minimal residual disease was highly sensitive and more accurate than flow cytometry and monitoring of B-cell...
Fewer than half of patients with unsatisfactory samples from fecal immunochemical tests completed follow-up testing within 15 months PHILADELPHIA...
Most were able to conceive and more than 60 percent gave birth SAN ANTONIO – Breast cancer patients who...
PHILADELPHIA – The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile...
SAN DIEGO – Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated...
ORLANDO, Fla. – The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated...
ORLANDO, Fla. – Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma...
REGN5459 had decreased binding affinity to T cells, resulting in an encouraging side effect profile and efficacy ORLANDO, Fla....
Results are from a median follow-up of three years SAN DIEGO – An adjuvant treatment regimen that included autogene...
Patients were pre- or perimenopausal with hormone receptor-positive, HER2-negative tumors SAN ANTONIO – In patients with hormone receptor-positive, HER2-negative,...
The multicancer early detection platform was developed based on methylation of cell-free DNA ORLANDO, Fla. – A liquid biopsy-based...
Drug has higher selectivity for PARP1, improving safety and tolerability SAN DIEGO – Saruparib, a selective inhibitor of poly-ADP...
SAN ANTONIO – Among patients with previously treated HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had...
ORLANDO, Fla. – Monotherapy with pembrolizumab (Keytruda) led to clinical responses in 89% of patients with unresectable metastatic desmoplastic...
PHILADELPHIA — Patients with metastatic melanoma that had relapsed on anti-PD-1 therapies or BRAF/MEK inhibitors did not respond as...
SAN ANTONIO – The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in...
SAN ANTONIO – A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival...
Results are from a five-year follow-up; long-term study is needed SAN ANTONIO – Almost all postmenopausal patients aged 50-69...
PHILADELPHIA – Today, the American Association for Cancer Research (AACR) and Pelotonia announced the establishment of a new grants...
New article in Clinical Cancer Research lists best practices, novel statistical methods, and suggestions for improving benefit-risk assessments PHILADELPHIA...
“SAN ANTONIO – Data from the NRG (NSABP B-39/RTOG 0413) trial indicated that ipsilateral breast tumor recurrence (IBTR) rates...
SAN ANTONIO – Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK)...
NEW ORLEANS – An interactive online LGBT cultural competency training program for oncologists may be acceptable, feasible, and improve...